Arkolith/Insider Trading/AVBP/Form 4

LaChapelle Robin

Chief Operating OfficerArriVent BioPharma, Inc. (AVBP) · full profile →Form 4 · filed Sep 23, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
5 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 19, 2024Option exercise(M)2K$2.28$6K112K
Sep 19, 2024Option exercise(M)12K$3.65$45K125K
Sep 19, 2024Option exercise(M)7K$2.28$16K110K
Sep 19, 2024Option exercise(M)3K$6.24$17K100K
Sep 19, 2024Option exercise(M)3K$2.28$7K103K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 19, 2024Option exercise(M)2K—$02K
Sep 19, 2024Option exercise(M)3K—$023K
Sep 19, 2024Option exercise(M)7K—$015K
Sep 19, 2024Option exercise(M)12K—$019K
Sep 19, 2024Option exercise(M)3K—$056K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-102146) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML